Single-cell dissection of cellular and molecular features underlying human cervical squamous cell carcinoma initiation and progression
Cervical squamous cell carcinoma (CESC) is a prototypical human cancer with well-
characterized pathological stages of initiation and progression. However, high-resolution …
characterized pathological stages of initiation and progression. However, high-resolution …
Unravelling roles of error-prone DNA polymerases in shaping cancer genomes
Mutagenesis is a key hallmark and enabling characteristic of cancer cells, yet the diverse
underlying mutagenic mechanisms that shape cancer genomes are not understood. This …
underlying mutagenic mechanisms that shape cancer genomes are not understood. This …
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an
irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor …
irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor …
Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions
J Herbst, K Pantel, K Effenberger, H Wikman - British Journal of Cancer, 2022 - nature.com
Human papilloma virus (HPV) is an infectious carcinogenic agent. Nearly all cervical
cancers are positive for one of the high-risk HPV subtypes. Although the introduction of the …
cancers are positive for one of the high-risk HPV subtypes. Although the introduction of the …
Single‐cell RNA‐sequencing dissects cellular heterogeneity and identifies two tumor‐suppressing immune cell subclusters in HPV‐related cervical adenosquamous …
X Li, M Zhang, T Lei, W Zou, R Huang… - Journal of Medical …, 2022 - Wiley Online Library
The intratumor heterogeneity of human papillomavirus (HPV)‐related cervical cancer
remains poorly defined. We performed single‐cell RNA sequencing on 18 046 individual …
remains poorly defined. We performed single‐cell RNA sequencing on 18 046 individual …
[HTML][HTML] Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
A Oaknin, CF Friedman, LD Roman, A D'Souza… - Gynecologic …, 2020 - Elsevier
Objective Somatic HER2 mutations occur in~ 5% of cervical cancers and are considered
oncogenic and associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine …
oncogenic and associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine …
The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma
KL Talia, N Banet, N Buza - Pathology, 2023 - Elsevier
Human epidermal growth factor receptor 2 (HER2) is a prognostic biomarker and
therapeutic target in carcinomas of the breast, stomach and colon. In 2018, clinical trial data …
therapeutic target in carcinomas of the breast, stomach and colon. In 2018, clinical trial data …
Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD‐L1 expression and enhancing T‐lymphocyte tumor‐killing activity
TX Sun, MY Li, ZH Zhang, JY Wang… - Phytotherapy …, 2021 - Wiley Online Library
The programmed cell death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) pathway is
abnormally expressed in cervical cancer cells. Moreover, PD‐1/PD‐L1 blockade reduces …
abnormally expressed in cervical cancer cells. Moreover, PD‐1/PD‐L1 blockade reduces …
Eight-lncRNA signature of cervical cancer were identified by integrating DNA methylation, copy number variation and transcriptome data
Q Zhong, M Lu, W Yuan, Y Cui, H Ouyang… - Journal of Translational …, 2021 - Springer
Background Copy number variation (CNV) suggests genetic changes in malignant tumors.
Abnormal expressions of long non-coding RNAs (lncRNAs) resulted from genomic and …
Abnormal expressions of long non-coding RNAs (lncRNAs) resulted from genomic and …
[PDF][PDF] Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT 'basket'trial
Background▪ HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs)
and are associated with poor overall survival (OS) in patients with metastatic disease. 1▪ …
and are associated with poor overall survival (OS) in patients with metastatic disease. 1▪ …